Persistent BK viremia does not increase intermediate-term graft loss but is associated with de novo donor-specific antibodies.

ABSTRACT: There are limited data regarding intermediate-term outcomes in patients with persistent BK viremia. Other viral infections have been implicated in the development of allosensitization through heterologous immunity, but the relationship between BK viremia and donor-specific antibodies (DSAs) is unexplored. In 2008, we initiated routine post-transplant BK viremia and DSA screening at our center; 785 kidney or kidney-pancreas transplant recipients were included in our study. Of these recipients, 132 (17%) recipients developed BK viremia during the study period. The median duration of BK viremia was 140 days (interquartile range=40-393 days), and persistent BK viremia was defined as lasting ≥140 days. Kaplan-Meier curves were generated to assess differences in patient and allograft survival on

SUBMITTER: Sawinski D 

PROVIDER: S-EPMC4378106 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature